New Antibody-Drug combo aims to tackle tough leukemia
NCT ID NCT01371630
First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times
Summary
This study is testing a drug called inotuzumab ozogamicin, which is like a smart bomb that targets and kills leukemia cells, combined with low-intensity chemotherapy. The goal is to find the best dose and see if this combo works better than standard treatments for patients with acute lymphoblastic leukemia, especially older adults or those whose cancer has returned. The trial involves about 276 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inotuzumab ozogamicin (a targeted antibody-drug conjugate) combined with chemotherapy drugs
- What this could lead to
- If successful, this could offer a more effective and less toxic treatment option for older or relapsed patients with acute lymphoblastic leukemia.
- What could go wrong
- This is an early-phase trial (Phase I/II), so the benefits are not yet proven. Side effects from the drug combination could be serious, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- Can engineered immune cells outsmart resistant blood cancers?